Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00937378 · ClinicalTrials.gov registry record · Phase 3
Treatment of Patients With Nocturia (Non-PK Study)
A Phase 3 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT00937378 is a Phase 3 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 326 participants.
The verdict
NCT00937378, a Phase 3 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
Interventions
- DRUG Placebo
- DRUG SER120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00937378
The ClinicalTrials.gov registry entry for NCT00937378 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Serenity Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00937378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00937378 about?
NCT00937378 is a clinical study titled "Treatment of Patients With Nocturia (Non-PK Study)". The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.
What is the current status of trial NCT00937378?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2009-06. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00937378?
The interventions under investigation include: Placebo (DRUG), SER120 (DRUG).
Who is sponsoring clinical trial NCT00937378?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.